Loading...
Loading...
In a report published Tuesday, Jefferies analyst Laurence Alexander initiated coverage on
Marrone Bio InnovationsMBII with a Buy rating and $17.00 price target.
In the report, Jefferies noted, “Marrone offers a pure-play on the theme of ‘a better ecosystem in a bag.' 2013-2014 hinges on the adoption curve of its first round of products, longer-term upside hinging on evidence the R&D platform supports a faster cadence of product launches and expansion into new markets such as row crops, animal health, seed treatments and public safety. We initiate coverage with a Buy rating. Jefferies served as Joint-Bookrunner in Marrone's August 2013 IPO.”
Marrone Bio Innovations closed on Monday at $13.34.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in